UPDATE 1-CSL says swine flu vaccine to boost 2010 growth

* Sees 14-24 percent profit growth in year ahead

* Swine flu vaccine sales key to growth

* Flags risk of regulatory action, lawsuit on plasma market (Adds details)

MELBOURNE, Aug 19 - Australian biotherapies group CSL Ltd expects swine flu vaccine sales to boost growth in the year ahead, the company said on Wednesday, after beating analysts' forecasts with a 63 percent rise in full year profit.

The company said it was focusing on expanding its influenza vaccine program, long a core, but small, part of its business, which is focused on blood plasma products.

"Orders for Novel A (H1N1) influenza or 'Swine Flu' vaccine are expected to provide a strong contribution to the fiscal year 2010 result," Chief Executive Brian McNamee said in a statement.

The company is looking for new growth paths, after U.S. competition regulators thwarted its planned $3.1 billion takeover of smaller U.S. rival Talecris Biotherapeutics Holdings Corp. The company decided to return most of the A$1.9 billion it raised for the deal to shareholders in June through a share buyback.

CSL expects net profit of A$1.16 billion to A$1.26 billion in fiscal 2010, based on currency rates over the past year, above analysts' forecasts for a net profit of A$1.15 billion.

Net profit rose to A$1.15 billion ($950.4 million) for the year to June, from A$702 million a year earlier, beating analysts' forecasts around A$1.01 billion, according to estimates tracker IBES.

The company began a six-week clinical trial of a swine flu vaccine in July, aiming to supply the vaccine to Australia before shipping it to countries in the northern hemisphere for their winter.

CSL warned that potential regulatory action or litigation could affect its earnings in the year ahead, after U.S. regulators raised concern about the big plasma players, like CSL and Baxter Inc , controlling the market.

A hospital in the U.S. state of Missouri has sued Baxter and CSL alleging they colluded to control production and drive up prices of plasma products.

CSL has said it believes there is no substance to the allegations and would defend any action against it vigorously. ($1=1.21 Australian Dollar)